Testosterone Prescribing Rates on the Rise Again After Nearly a Decade of Decline

After a decrease from 2013 to 2021, the share of male patients prescribed testosterone replacement therapy has been increasing, reaching 0.93% in 2025 and 0.95% in the first half of 2026. This resurgence is observed across all age groups 30 and older, with men aged 50-64 showing the highest prevalence at 1.57% in 2025. The initial decline followed concerns about cardiovascular safety, but the current trend indicates a renewed increase in the use of these therapies for low testosterone levels.